Talbutal

Summary

Talbutal (CHEMBL1200802) is an approved small molecule (ATC N05CA07).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CA07
• Chemistry: 224.26 Da · C11H16N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200802
Name	Talbutal
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8275
ATC	N05CA07
Molecular formula	C11H16N2O3
Molecular weight	224.26
InChIKey	BJVVMKUXKQHWJK-UHFFFAOYSA-N

SMILES: CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C

IUPAC name: 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione

Also known as: Lotusate, Talbutal, TALBUTAL, SID170465408, talbutal

Patent coverage: 837 distinct patent families (3,504 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).